RAGE: a novel biological and genetic marker for vascular disease
- PMID: 19275767
- DOI: 10.1042/CS20080494
RAGE: a novel biological and genetic marker for vascular disease
Abstract
RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.
Similar articles
-
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes.Microvasc Res. 2008 May;76(1):52-6. doi: 10.1016/j.mvr.2007.09.004. Epub 2007 Oct 5. Microvasc Res. 2008. PMID: 18474381
-
The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease.Clin Biochem. 2008 Aug;41(12):981-5. doi: 10.1016/j.clinbiochem.2008.05.007. Epub 2008 May 27. Clin Biochem. 2008. PMID: 18538667
-
Receptor for advanced glycation end products (RAGE)--soluble form (sRAGE) and gene polymorphisms in patients with breast cancer.Cancer Invest. 2007 Dec;25(8):720-5. doi: 10.1080/07357900701560521. Cancer Invest. 2007. PMID: 18058469
-
Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases.Rheumatology (Oxford). 2009 Oct;48(10):1190-6. doi: 10.1093/rheumatology/kep199. Epub 2009 Jul 9. Rheumatology (Oxford). 2009. PMID: 19589888 Review.
-
RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts.J Leukoc Biol. 2009 Sep;86(3):505-12. doi: 10.1189/jlb.0409230. Epub 2009 May 28. J Leukoc Biol. 2009. PMID: 19477910 Review.
Cited by
-
Relevance of Receptor for Advanced Glycation end Products (RAGE) in Murine Antibody-Mediated Autoimmune Diseases.Int J Mol Sci. 2019 Jul 1;20(13):3234. doi: 10.3390/ijms20133234. Int J Mol Sci. 2019. PMID: 31266174 Free PMC article.
-
Punicic acid alleviates methylglyoxal-induced oocyte dysfunction during in vitro maturation in mouse species.PLoS One. 2025 Mar 25;20(3):e0314602. doi: 10.1371/journal.pone.0314602. eCollection 2025. PLoS One. 2025. PMID: 40131868 Free PMC article.
-
Danger signals activating the immune response after trauma.Mediators Inflamm. 2012;2012:315941. doi: 10.1155/2012/315941. Epub 2012 Jun 19. Mediators Inflamm. 2012. PMID: 22778496 Free PMC article. Review.
-
Remote Ischemic Postconditioning Protects against Myocardial Ischemia-Reperfusion Injury by Inhibition of the RAGE-HMGB1 Pathway.Biomed Res Int. 2018 Jan 23;2018:4565630. doi: 10.1155/2018/4565630. eCollection 2018. Biomed Res Int. 2018. PMID: 29789792 Free PMC article.
-
Impact of serum high mobility group box 1 and soluble receptor for advanced glycation end-products on subclinical atherosclerosis in patients with granulomatosis with polyangiitis.PLoS One. 2014 Apr 28;9(4):e96067. doi: 10.1371/journal.pone.0096067. eCollection 2014. PLoS One. 2014. PMID: 24776932 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical